KPRX · Kiora Pharmaceuticals Inc
Market Cap
$10.53M
Shares
4.42M
Volume · Oct 20
23.46K
Avg daily vol (3M)
15.75K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.33
Open$2.38
Day$2.32–2.41
52W close$1.80–2.86
Avg vol 30d15K
Short int3K · 0.1% float · 1.0d
Short vol44%
DataJan 2020–Oct 2026
Filing10-Q · Aug 7
Up next
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$10.99M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-81.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$16.84M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+54.9%
Year over year · more shares
Price change (1Y)
-12.2%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−10%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−1%
trailing
YTD return
+18%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
2 of 25 funds reported for Sep 30 · net +11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -14.6% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
25 holders — mid 3-yr range
Squeeze score
18
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−403%
Y/Y
Free cash flow
$-10.1M
Balance sheet
$8.7M
net cash
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
3.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−10%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
2 of 25 funds reported for Sep 30 · net +11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -14.6% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
25 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 50%
Range high $3
vs 200-day avg -3%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KPRX
this stock
Kiora Pharmaceuticals Inc
|
$10.53M | +18.3% | -100.0% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KPRX | -5.7% | -14.0% | -0.9% | -9.0% | +18.3% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -4.5% | -13.5% | -8.9% | -9.8% | +5.5% |